Table 1 Patient and tumor characteristics
Total N=237 | Pathologic complete response not achieved N=212; 89% | Pathologic complete response achieved N=25; 11% | P-valuea | |
|---|---|---|---|---|
Continuous variables: mean (Std. dev.) | ||||
Age | 54.3 (12.2) | 54.8 (12.4) | 49.6 (10.2) | 0.0328 |
Age at menarche | 12.7 (1.7) Unknown 38 | 12.8 (1.8) Unknown 32 | 12.3 (1.4) Unknown 6 | 0.1212 |
Body mass index | 29.0 (7.4) Unknown 53 | 28.9 (7.6) Unknown 48 | 29.4 (5.4) Unknown 5 | 0.3895 |
Pre-therapy tumor size | 4.2 (2.7) Unknown 22 | 4.4 (2.7) Unknown 19 | 3.2 (1.9) Unknown 3 | 0.0245 |
Ki-67 labeling index in % | 41.8 (28.8) | 37.9 (27.4) | 75 (15.6) | <0.0001 |
Estrogen receptor H-score | 204 (98.5) | 217.4 (89.9) | 91.8 (100.2) | <0.0001 |
Progesterone receptor H-score | 110.8 (104) | 119.3 (103.9) | 38.6 (76.8) | <0.0001 |
Categorical variables: N (%) | ||||
Menopausal status | ||||
Premenopausal | 107 (45%) | 89 (42%) | 18 (72%) | 0.0041 |
Postmenopausal | 127 (54%) | 121 (57%) | 6 (24%) | |
Unknown | 3 (1%) | 2 (1%) | 1 (4%) | |
Race | ||||
Caucasian | 218 (92%) | 195 (92%) | 23 (92%) | 0.7734 |
Black | 16 (7%) | 14 (7%) | 2 (8%) | |
Asian | 1 (<1%) | 1 (<1%) | 0 | |
Others | 2 (<1%) | 2 (<1%) | 0 | |
Pre-therapy lymph node status | ||||
Core biopsy positive | 88 (37%) | 77 (36%) | 11 (44%) | 0.7979 |
Core biopsy negative | 94 (40%) | 85 (40%) | 9 (36%) | |
Unknown | 55 (23%) | 50 (24%) | 5 (20%) | |
Pre-therapy nuclear grade | ||||
Nuclear grade 1 or 2 | 112 (47%) | 110 (52%) | 2 (8%) | <0.0001 |
Nuclear grade 3 | 109 (46%) | 87 (41%) | 22 (88%) | |
Unknown | 16 (7%) | 15 (7%) | 1 (4%) | |
Histology | ||||
Ductal | 199 (84%) | 174 (82%) | 25 (100%) | 0.0862 |
Lobular | 30 (13%) | 30 (14%) | 0 | |
Others | 8 (3%) | 8 (4%) | 0 | |
Progesterone receptor status | ||||
Positive | 173 (73%) | 164 (77%) | 9 (36%) | <0.0001 |
Negative | 64 (27%) | 48 (23%) | 16 (64%) | |
HER2 status | ||||
Negative | 201 (85%) | 180 (85%) | 21 (84%) | 1.0000 |
Equivocal | 36 (15%) | 32 (15%) | 4 (16%) | |
